Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer

Irish Journal of Medical Science

Volumn 178, Issue 2, 2009, Pages 201-208

  Barry, Mitchel ^a   Cahill, R A ^a   Roche Nagle, G ^a   Neilan, T G ^a   Treumann, A ^a   Harmey, J H ^a   Bouchier Hayes, D J ^b  

^a BEAUMONT HOSPITAL   (Ireland)

^b MATER PRIVATE HOSPITAL   (Ireland)

Author keywords

COX 2 inhibitors; Escape process; Lipoxygenase inhibitors; Tumour

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 6 OXOPROSTAGLANDIN F1 ALPHA; CYCLOOXYGENASE 2; DOCEBENONE; LIPOXYGENASE; PROSTACYCLIN; CYCLOOXYGENASE 2 INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME INHIBITION; KNOCKOUT MOUSE; LUNG METASTASIS; MASS SPECTROMETRY; MOUSE; NONHUMAN; TUMOR ESCAPE; TUMOR VOLUME; URINALYSIS; ANIMAL; BREAST TUMOR; DISEASE COURSE; DRUG EFFECTS; ENZYMOLOGY; FEMALE; METABOLISM; RANDOMIZATION;

ANIMALS; BREAST NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; FEMALE; LIPOXYGENASE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; RANDOM ALLOCATION;

EID: 67649547275     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11845-009-0335-3     Document Type: Article

References (43)

1. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cyclo-oxygenase-2 expression in breast cancer. Cancer Res 62(3):632-635
2. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge T, Yosida S (2001) Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 91(2):333-338. doi: 10.1002/ 1097-0142(20010115)91:2<333::AID-CNCR1006>3.0.CO;2-N
3. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and 2 in human colorectal cancer. Cancer Res 55(17):3785-3789
4. Juo YE, Rew JS, Seo YH, Choi SK, Kim YJ, Park CS, Kim SJ (2003) Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression in tumour angiogenesis in gastric cancer. J Clin Gastroenterol 37(1):28-33. doi: 10.1097/00004836-200307000-00009
5. Li W, Xu RJ, Zhang HH, Jiang LH (2006) Overexpression of cyclooxygenase-2 correlates with tumour angiogenesis in endometrial carcinoma. Int J Gynecol Cancer 16(4):1673-1678. doi: 10.1111/ j.1525-1438.2006.00408.x
6. Tjandrawinata RR, Dahiya R, Hughes-Fulford M (1997) Induction of cyclooxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 75(8):1111-1118
7. Pai R, Soreghan B, Szabo IL et al (2002) Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8:289-293. doi: 10.1038/nm0302-289
8. Tsujii M, Kawano S, Tsuji S, Sawoaka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716. doi: 10.1016/S0092-8674(00)81433-6
9. Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar K, Luo J, Zhu L, Lin Y, Huang M, Dohadwala M, Batra RK, Dubinett SM (2003) Tumour cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 9:961-968
10. Li G, Yang T, Yan J (2002) Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumour cells. Biochem Biophys Res Commun 299:886-890. doi: 10.1016/S0006-291X(02)02707-9
11. Tsujii M, Kawano S, DuBois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94:3336-3340. doi: 10.1073/pnas.94.7.3336
12. Romano M, Catalano A, Nutini M, D'Urbano E, Crescenzi C, Claria J, Libner R, Davi G, Procopio A (2001) 5-Lipoxygenase regulates malignant mesothelial cell survival: Involvement of endothelial growth factor. FASEB J 15:2326-2336. doi: 10.1096/fj.01-0150com
13. Cao Y, Pearmann AT, Zimmerman GA, McIntyre TM, Prescott SM (2000) Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 97:11280-11285. doi: 10.1073/pnas.200367597
14. Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E, Bouchier-Hayes DJ (2002) Cyclooxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer 87:231-237. doi: 10.1038/sj.bjc.6600462
15. Roche-Nagle G, Connolly EM, Eng M, Bouchier-Hayes DJ, Harmey JH (2004) Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br J Cancer 91(2):359-365
16. Kundu N, Fulton A (2002) Selective cyclooxygenase (cox)-1 or cox-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 62:2343-2346
17. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL (1999) Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 59:2223-2228
18. Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ (1999) Enhancement of tumour response to radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91:1501-1504. doi: 10.1093/ jnci/91.17.1501
19. Tong WG, Ding XZ, Witt RC, Adrian TE (2002) Lipoxygenase inhibitors attenuate growth of human pancreatic xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 1:929-935
20. Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ (1999) The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 81(8):1311-1317. doi: 10.1038/sj.bjc.6694369
21. Pulaski BA, Ostrand-Rosenberg S (2001) Mouse 4T1 breast tumour model. Curr Protoc Immunol. Chap 20: Unit 20.2
22. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and the risk of fatal cancer. Cancer Res 53:1322-1327
23. Chapple KS, Cartwright EJ, Howcroft G, Tisbury A, Bonifer C, Scott N, Windsor AC, Guillou PJ, Markham AF, Coletta PL, Hull MA (2000) Localization of cyclooxygenase-2 in human sporadic colorectal adenoma. Am J Pathol 156:545-553
24. Shattuck-Brandt RL, Varilet GW, Radhika A, Yang F, Washington MK, DuBois RN (2000) Cyclooxygenase-2 expression is increased in the subepithelial myofibroblasts of colon and caecal carcinoma from IL-10 (-/-) mice. Gastroenterology 118:337-345. doi: 10.1016/S0016-5085(00)70216-2
25. Kinzler KW, Vogelstein B (1998) Landscaping the cancer terrain. Science 280:1036-1037. doi: 10.1126/science.280.5366.1036
26. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105(11):1589-1594. doi: 10.1172/JCI9621
27. Hanahan D, Folkmann J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 86:353-364. doi: 10.1016/ S0092-8674(00)80108-7
28. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris JE (2001) Dose response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 21:3425-3432
29. Jang TJ, Jung HG, Jung KH, O Min Ku (2002) Chemopreventive effect of celecoxib and expression of cyclooxygense-1 and cyclooygenase-2 on chemically induced rat tumour models. Int J Exp Pathol 83:173-182. doi: 10.1046/j.1365-2613.2002.00228.x
30. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN (1997) Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99:2254-2259. doi: 10.1172/JCI119400
31. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE (2000) Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumour model. Oncol Rep 7:1377-1381
32. Reddy BS, Maruyama H, Kelloff G (1987) Dose related inhibition of colon carcinogenesis by dietary piroxicam; a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumour development. Cancer Res 47:5340-5346
33. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trasaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in APC delta 716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 87:803-809. doi: 10.1016/ S0092-8674(00)81988-1
34. Lagakos SW (2006) Time-to-event analyses for long-term treatments - the APPROVe trial. N Engl J Med 355(2):113-117. doi: 10.1056/NEJMp068137
35. Kargman S, Vickers PJ, Evan JF (1992) A23187 induces translocation of 5-lipoxygenase in osteosarcoma cells. J Cell Biol 119:1701-1709. doi: 10.1083/jcb.119.6.1701
36. Baodo RJ, Pardridge WM, Vinters HV, Black KL (1992) Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumours: Evidence for the expression of a multitranscript family. Proc Natl Acad Sci USA 89:9044-9048. doi: 10.1073/pnas.89.19.9044
37. Henning P, Ding XZ, Tong WG, Schneider MB, Standop J, Freiss H, Buchler MW, Pour PM, Adrian TE (2002) 5-Lipoxygenase and leukotrienes B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 161:421-428
38. Gupta S, Srivastara M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar N (2001) Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91:737-743. doi: 10.1002/ 1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F
39. Hoper MM, Voelkel NF, Bates TO, Allard JD, Horan M, Sheppard D, Tuder RM (1997) Prostaglandins induce vascular endothelial growth factor in a human monocyte cell line and rat lungs via Camp. Am J Respir Cell Mol Biol 17:748-756
40. Liu XH, Kirschenbaum A, Lu M, Yao S, Dosoretz A, Holland JF, Levine AC (2002) Prostaglandin E2 induces hypoxia inducible factor-1-alpha stabilization and nuclear localization in a prostate cancer cell line. J Biol Chem 277:50081-50086. doi: 10.1074/jbc.M201095200
41. Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, Das R, Jett M, Mulshine JL (2001) Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 15(11):2007-2009
42. Tsukada T, Nakashima K, Shirakawa S (1986) Arachidonate 5-lipoxygenase inhibitors show potent antiproliferative effects on human leukaemia cell lines. Biochem Biophys Res Commun 140:832-836. doi: 10.1016/ 0006-291X(86)90709-6
43. Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071-1080. doi: 10.1056/NEJMoa050405